{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:46:39Z","timestamp":1785861999003,"version":"3.56.0"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Pulmonary hypertension (PH) is defined as elevated pressures in the pulmonary artery and is associated with significant morbidity and mortality. The World Health Organization classifies PH into 5 distinct groups based on underlying etiology, pathology, and modality of treatment. Therapeutic approach may be challenging due to the extensive spectrum of causes and underlying mechanisms mediating PH. The 5 groups include pulmonary arterial hypertension (group 1), PH secondary to left heart disease (group 2), PH secondary to chronic lung disease (group 3), chronic thromboembolic pulmonary hypertension (group 4), and PH due to miscellaneous causes (group 5). Although significant progress has been made in the treatment of group 1 PH, there is a continued need to develop new therapies for all types of PH. Additionally, most treatments currently available improve functional capacity and symptoms but without a significant benefit in mortality. In this review, we aim to describe the various etiologies of PH and their established pharmacotherapies, as well as expand on emerging therapeutic options for each group.<\/jats:p>","DOI":"10.1097\/crd.0000000000000647","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:01:09Z","timestamp":1706691669000},"page":"494-501","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological Update and Emerging Treatments of Pulmonary Hypertension"],"prefix":"10.1097","volume":"33","author":[{"given":"Shazli","family":"Khan","sequence":"first","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samaritan Medical Center, Watertown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Patail","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut School of Medicine, Hartford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Spira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg M.","family":"Lanier","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"R1-20251003","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"R2-20251003","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review.","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"R3-20251003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1513\/pats.200510-112JH","article-title":"Pulmonary arterial hypertension.","volume":"3","author":"Rubin","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"R4-20251003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pcad.2012.07.002","article-title":"WHO group 1 pulmonary arterial hypertension: current and investigative therapies.","volume":"55","author":"Ventetuolo","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"R5-20251003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension.","volume":"21","author":"Bisserier","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"R7-20251003","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-20251003","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"R9-20251003","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20251003","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"R11-20251003","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R12-20251003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R13-20251003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension.","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"R14-20251003","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.","volume":"48","author":"Voswinckel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R15-20251003","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R16-20251003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"R17-20251003","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial.","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20251003","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension.","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"R19-20251003","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.","volume":"58","author":"Asaki","year":"2015","journal-title":"J Med Chem"},{"key":"R20-20251003","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R21-20251003","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R22-20251003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"R23-20251003","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"R24-20251003","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension.","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"R25-20251003","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","article-title":"Long-Term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension.","volume":"39","author":"Souza","year":"2022","journal-title":"Adv Ther"},{"key":"R26-20251003","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20251003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"R28-20251003","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R29-20251003","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension.","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R30-20251003","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension.","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"R31-20251003","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension.","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"R32-20251003","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension.","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"R35-20251003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/2045894020908782","article-title":"Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension.","volume":"10","author":"Saygin","year":"2020","journal-title":"Pulm Circ"},{"key":"R36-20251003","doi-asserted-by":"crossref","first-page":"2102356","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.","volume":"60","author":"Galkin","year":"2022","journal-title":"Eur Respir J"},{"key":"R37-20251003","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"R39-20251003","doi-asserted-by":"crossref","first-page":"20458940211057071","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension.","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm Circ"},{"key":"R40-20251003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14797\/CBHS2234","article-title":"Novel treatment pathways in pulmonary arterial hypertension.","volume":"17","author":"Qaiser","year":"2021","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"R42-20251003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13287-019-1162-8","article-title":"Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies.","volume":"10","author":"Ding","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"R43-20251003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/ijms22031179","article-title":"Genetic delivery and gene therapy in pulmonary hypertension.","volume":"22","author":"Rai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R44-20251003","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/FJC.0000000000001155","article-title":"Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension.","volume":"79","author":"Adie","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"R46-20251003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1573403X09666131117164122","article-title":"Pulmonary hypertension: types and treatments.","volume":"11","author":"Rose-Jones","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"R47-20251003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MCP.0000000000001002","article-title":"Group 2 pulmonary hypertension: from diagnosis to treatment.","volume":"29","author":"Frantz","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"R48-20251003","doi-asserted-by":"crossref","first-page":"100980","DOI":"10.1016\/j.cpcardiol.2021.100980","article-title":"Outcomes in hospitalization in patients with heart failure undergoing remote pulmonary artery pressure monitoring: a systematic review and meta-analysis of major trials.","volume":"47","author":"Thakker","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"R49-20251003","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: emperor-preserved trial.","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"R50-20251003","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"R51-20251003","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial.","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"R52-20251003","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HCO.0000000000000791","article-title":"Pulmonary hypertension associated with left-sided heart failure.","volume":"35","author":"Adler","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"R53-20251003","doi-asserted-by":"crossref","first-page":"1064290","DOI":"10.3389\/fcvm.2023.1064290","article-title":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.","volume":"10","author":"Joshi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R55-20251003","doi-asserted-by":"crossref","first-page":"107180","DOI":"10.1016\/j.vph.2023.107180","article-title":"The future of group 2 pulmonary hypertension: exploring clinical trials and therapeutic targets.","volume":"151","author":"Awada","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"R56-20251003","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.healun.2016.07.015","article-title":"Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: a pilot study.","volume":"35","author":"Finch","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R57-20251003","doi-asserted-by":"crossref","first-page":"2045894018790905","DOI":"10.1177\/2045894018790905","article-title":"Levosimendan in pulmonary hypertension and right heart failure.","volume":"8","author":"Hansen","year":"2018","journal-title":"Pulm Circ"},{"key":"R58-20251003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease.","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res"},{"key":"R60-20251003","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia.","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"R61-20251003","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.00176312","article-title":"Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.","volume":"42","author":"Blanco","year":"2013","journal-title":"Eur Respir J"},{"key":"R62-20251003","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0167-5273(11)70492-2","article-title":"Pulmonary hypertension due to chronic lung disease: updated recommendations of the cologne consensus conference 2011.","volume":"154","author":"Hoeper","year":"2011","journal-title":"Int J Cardiol"},{"key":"R63-20251003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"R64-20251003","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 pulmonary hypertension: from bench to bedside.","volume":"130","author":"Singh","year":"2022","journal-title":"Circ Res"},{"key":"R65-20251003","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.recesp.2022.10.015","article-title":"Comments on the 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"76","year":"2023","journal-title":"Rev Esp Cardiol"},{"key":"R66-20251003","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030418","article-title":"Pharmacology and emerging therapies for group 3 pulmonary hypertension due to chronic lung disease.","volume":"16","author":"Gonzales","year":"2023","journal-title":"Pharmaceuticals"},{"key":"R67-20251003","doi-asserted-by":"crossref","first-page":"L238","DOI":"10.1152\/ajplung.00142.2016","article-title":"Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and group III pulmonary hypertension.","volume":"311","author":"Chen","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R68-20251003","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1183\/09031936.02.00272002","article-title":"Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD.","volume":"20","author":"Di Stefano","year":"2002","journal-title":"Eur Respir J"},{"key":"R69-20251003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"R71-20251003","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension.","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R72-20251003","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","article-title":"Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry.","volume":"141","author":"Mayer","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R73-20251003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R74-20251003","first-page":"749","article-title":"Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.","volume":"39","author":"Khaybullina","year":"2014","journal-title":"P T"},{"key":"R75-20251003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.CIR.103.1.10","article-title":"Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension.","volume":"103","author":"Feinstein","year":"2001","journal-title":"cIRCULATION"},{"key":"R76-20251003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MCP.0000000000000898","article-title":"Update on balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension.","volume":"28","author":"Lang","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"R77-20251003","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1183\/09031936.00012914","article-title":"Right ventricular reverse remodelling after balloon pulmonary angioplasty.","volume":"43","author":"Fukui","year":"2014","journal-title":"Eur Respir J"},{"key":"R78-20251003","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.","volume":"10","author":"Ja\u00efs","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R79-20251003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1183\/09031936.00201612","article-title":"Chronic thromboembolic pulmonary hypertension: role of medical therapy.","volume":"41","author":"Pepke-Zaba","year":"2013","journal-title":"Eur Respir J"},{"key":"R80-20251003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCIMAGING.112.000276","article-title":"Noninvasive assessment of pulmonary hemodynamics in patients with chronic thromboembolic pulmonary hypertension by high temporal resolution phase-contrast MRI: correlation with simultaneous invasive pressure recordings.","volume":"6","author":"Kreitner","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"R81-20251003","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R82-20251003","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.","volume":"52","author":"Ja\u00efs","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R83-20251003","doi-asserted-by":"crossref","first-page":"2101694","DOI":"10.1183\/13993003.01694-2021","article-title":"Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.","volume":"60","author":"Ogo","year":"2022","journal-title":"Eur Respir J"},{"key":"R85-20251003","first-page":"46","article-title":"The myriad presentations of sickle cell disease-related pulmonary hypertension.","volume":"20","author":"Prohaska","year":"2021","journal-title":"Adv Pulm Hypertens"},{"key":"R86-20251003","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ccm.2013.08.005","article-title":"World Health Organization group 5 pulmonary hypertension.","volume":"34","author":"Lahm","year":"2013","journal-title":"Clin Chest Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:46:14Z","timestamp":1785858374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000647","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}